Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

Puma Biotechnology, Inc.

Rank #13ValueWatchlistCompare with other stocks

PBYI · Nasdaq · Healthcare

Puma Biotechnology, Inc. (PBYI) — Rank #13 by gross profitability (GP/assets 0.88) · ROE 22.5% · Piotroski F-Score 7 / 9.

As-of 2026-10-30 · CIK 0001401667 · all metrics point-in-time as of the filing date.

About

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.

Show more

It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc.

was founded in 2010 and is headquartered in Los Angeles, California.

Industry
Biotechnology
Sector
Healthcare
State
DE
Filer Category
Accelerated filerSmaller reporting company
Fiscal Year End
December 31

Company Snapshot

P/E and dividend yield are the primary valuation lenses for mature businesses.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

179

Industry

Biotechnology

Exchange

Nasdaq

10/12

Flags passed

PBYI fails 1 critical flag

Passes 10 of 12 quality flags, 1 caution

  • FAIL
    Revenue declining YoY

    Revenue contracted year over year

  • CAUTION
    Dilution above 2%

    Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation

  • PASS
    Gross margin holding
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Revenue growth accelerating · Operating leverage expanding · Sequential beat (rev + EPS)

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.88
Return on equity
22.5%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.39
Current ratio
2.91×
Net cash
$93.90M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
3.0%

Growth

0/2 pass
Revenue growth
-0.9%
Piotroski F-Score
7 / 9
Share dilution
3.2%

Dividend yield and payout ratio are the primary reads at this stage (trailing P/E — see valuation above).

Profitability

Does it make money well?

Warning: Revenue declining YoY · GP/assets 0.88

Gross profitability (GP / assets)

0.88

Primary signal (Novy-Marx).

2nd of 12 SIC 2834 peers

Return on equity

22.5%

Gross margin

74.5%

7th of 12 SIC 2834 peers

Revenue growth (YoY)

-0.9%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

0.0%

Revenue CAGR (5Y)

0.3%

Earnings CAGR (3Y)

2396.3%

FCF CAGR (3Y)

—

Cash Flow Health

Is the cash real?

No warning flags · FCF 34% above net income

Free cash flow

$41.73M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

34.1%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

3.0%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

Caution: Dilution above 2% · net cash $93.90M, F-Score 7/9

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.39

3rd of 12 SIC 2834 peers (best = lowest)

Current ratio

2.91×

6th of 12 SIC 2834 peers

Quick ratio

2.57×

Net cash

$93.90M

Cash & equivalents minus total debt.

Piotroski F-Score

7 / 9

Fundamental-strength score (0-9).

Valuation

Is the price reasonable?

No warning flags

Capital allocation quality

Composite score

3.0 / 5

Good
Share count trend
3.2%1/5 Weak
Buyback timing
N/AN/A
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory(deleveraging)
19.0%5/5 Strong

Lifecycle Phase History

20202025
Decline
Startup
Value

Price History

PBYI+35.2% · +6.2% CAGRSPY+82.9% · +12.8% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports